Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients.
Am J Addict
; 29(1): 73-76, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31626394
ABSTRACT
BACKGROUND:
Prerequisite opioid withdrawal symptoms prior to buprenorphine induction are unacceptable to many patients. We assessed whether transdermal buprenorphine minimized withdrawal while bridging to sublingual therapy among hospital inpatients.METHODS:
Retrospective chart review of (n = 23) inpatients with opioid use disorder or opioid dependence due to chronic pain.RESULTS:
Of 23 inpatients, 65% transitioned without symptoms, while 35% experienced mild withdrawal. Ninety-six percent completed planned hospitalizations, with 83% engaged in treatment 4 weeks post-discharge. DISCUSSION ANDCONCLUSIONS:
Bridging to sublingual therapy with transdermal buprenorphine patches was feasible without withdrawal symptoms. SCIENTIFICSIGNIFICANCE:
This strategy may facilitate buprenorphine therapy in hospital inpatients. (Am J Addict 2019;001-4).
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
/
8_ODS3_consumo_sustancias_psicoactivas
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Abstinência a Substâncias
/
Buprenorfina
Tipo de estudo:
Observational_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Addict
Ano de publicação:
2020
Tipo de documento:
Article